We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 227 of 309 for:    hepatitis b | Recruiting, Not yet recruiting, Available Studies

Studies of Small DNA Virus Encoded Oncogenes in Viral Carcinogenesis Using Laboratory Model Systems

This study is not yet open for participant recruitment.
Verified June 2017 by Heba Momen kamel, Assiut University
Sponsor:
ClinicalTrials.gov Identifier:
NCT03188315
First Posted: June 15, 2017
Last Update Posted: June 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Heba Momen kamel, Assiut University
  Purpose

Cancer is a devastating disease, presenting an immense disease burden to affected individuals and their families as well as health care systems with 10.9 million new cases and 6.7 million deaths per year. Approximately 12% of human cancers worldwide are caused by oncoviruses infection with more than 80% of cases occurring in the developing world.

Tumor viruses can be classified into two groups based on their genetic material;

  1. DNA tumor viruses:

    1. Small DNA tumor viruses (Papilloma viruses, Polyoma viruses and adenoviruses).
    2. Complex DNA tumor viruses (Herpes viruses and Hepatitis B viruses).
  2. RNA tumor viruses ( Hepatitis C viruses and human T-cell leukemia virus "HTLV").

There are around 100 types of HPV, with different variations in their genetic and oncogenic potential [5]. Thus, HPV genotypes are divided into 2 groups based on their vulnerability; High risk HPV (HR-HPV) and low risk HPV (LR-HPV).

The HPV genome encodes several oncoproteins [5]. E6 and E7 are the main genes responsible for cell transformation mediated by HR-HPV, and they modulate the activities of cellular proteins that regulate the cell cycle. Thus, the presence of E6/E7 can be a specific marker for diagnosing precancerous lesions by HPV.

Knowledge of the etiology of virus-mediated carcinogenesis, the networking of pathways involved in the transition from infection to cancer and the risk factors associated with each type of cancer, all suggest prophylactic and therapeutic strategies that may reduce the risk of virus-mediated cancer.


Condition Intervention
DNA Virus Infections Genetic: HPV oncogenes

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Primary Purpose: Basic Science
Official Title: Studies of Small DNA Virus Encoded Oncogenes in Viral Carcinogenesis Using Laboratory Model Systems

Further study details as provided by Heba Momen kamel, Assiut University:

Primary Outcome Measures:
  • carcinogenesis [ Time Frame: 6 months ]
    developing cancer cervix


Estimated Enrollment: 40
Anticipated Study Start Date: September 1, 2017
Estimated Study Completion Date: February 28, 2018
Estimated Primary Completion Date: February 28, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: cases
HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
Genetic: HPV oncogenes
PCR and oncogenes detection
Active Comparator: control
HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
Genetic: HPV oncogenes
PCR and oncogenes detection

  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age: 18 - 65 years old.
  • Women who are positive for HPV diagnosed by routine screening.
  • Women willing to participate in the study and sign an informed consent

Exclusion Criteria:

  • Age extremes (less than 18 years old or more than 65 years old).
  • Immuno-comprised patients, patients under steroid therapy or chemotherapy, or patients with serious medical illness that could affect their immune system.
  • Unknown medical history.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Heba Momen kamel, assistant lecturer, Assiut University
ClinicalTrials.gov Identifier: NCT03188315     History of Changes
Other Study ID Numbers: 17200086
First Submitted: June 13, 2017
First Posted: June 15, 2017
Last Update Posted: June 15, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Virus Diseases
Carcinogenesis
DNA Virus Infections
Neoplastic Processes
Neoplasms
Pathologic Processes